ArticleThe Journal of clinical investigation2012
Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.
- Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.Nature reviews. Endocrinology · 2024Guideline
- Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans.The Journal of clinical endocrinology and metabolism · 2025Trial
- Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions.JCI insight · 2018Trial
- Kisspeptin modulates sexual and emotional brain processing in humans.The Journal of clinical investigation · 2017Trial
- Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone.Journal of endocrinological investigation · 2026Article
- Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders.Andrology · 2026Review
- Position statement on macroprolactinemia from the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML).Archives of endocrinology and metabolism · 2025Article
- Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects.Pituitary · 2025Article
- Kisspeptins Regulating Fertility: Potential Future Therapeutic Approach in Infertility Treatment.Journal of clinical medicine · 2025Review
- Kisspeptin and neurokinin B: roles in reproductive health.Physiological reviews · 2025Review
- The kisspeptin analog C6 reverses reproductive dysfunction in a mouse model of hyperprolactinemia.Reproduction (Cambridge, England) · 2025Article
- Article
- Thyroid-reproductive axis interplay: immunological mechanisms and implications for female reproductive health.Frontiers in cellular and infection microbiology · 2025Review
- Prolactin: structure, receptors, and functions.Reviews in endocrine & metabolic disorders · 2024Review
- Macroprolactinoma in an adolescent female with primary amenorrhoea.Endocrinology, diabetes & metabolism case reports · 2024Article
- Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma.Journal of the Endocrine Society · 2024Article
- Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.Journal of endocrinological investigation · 2024Review
- Current Insights in Prolactin Signaling and Ovulatory Function.International journal of molecular sciences · 2024Review
- The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.Endocrine reviews · 2024Review
- Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.Reviews on recent clinical trials · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperprolactinemia is the most common cause of hypogonadotropic anovulation and is one of the leading causes of infertility in women aged 25-34. Hyperprolactinemia has been proposed to block ovulation through inhibition of GnRH release. Kisspeptin neurons, which express prolactin receptors, were recently identified as major regulators of GnRH neurons. To mimic the human pathology of anovulation, we continuously infused female mice with prolactin. Our studies demonstrated that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin secretion, and diminished kisspeptin expression. Kisspeptin administration restored gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a major role in hyperprolactinemic anovulation. Our studies indicate that administration of kisspeptin may serve as an alternative therapeutic approach to restore the fertility of hyperprolactinemic women who are resistant or intolerant to dopamine agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.